Pasireotide - Novartis

Drug Profile

Pasireotide - Novartis

Alternative Names: pasireotide-LAR; Signifor; Signifor LAR; SOM-230; SOM-230-LAR; SOM230C

Latest Information Update: 31 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Developer H. Lee Moffitt Cancer Center and Research Institute; Novartis; UNC Lineberger Comprehensive Cancer Center; University of Arkansas for Medical Sciences; University of Miami
  • Class Antineoplastics; Cyclic peptides; Macrocyclic compounds; Oligopeptides; Peptidomimetics
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors; Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Vascular endothelial growth factor A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acromegaly; Pituitary ACTH hypersecretion; Neuroendocrine tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pituitary ACTH hypersecretion
  • Registered Acromegaly; Gigantism
  • Phase III Pancreatic disorders
  • Phase II Cluster headache; Gastrointestinal disorders; Hepatocellular carcinoma; Meningioma; Neuroendocrine tumours; Pituitary cancer; Prostate cancer; Uveal melanoma
  • No development reported Gastrointestinal cancer; Malignant melanoma; Merkel cell carcinoma; Pancreatic cancer; Radiation injuries
  • Discontinued Carcinoid tumour

Most Recent Events

  • 19 Apr 2018 Registered for Pituitary ACTH Hypersecretion in Japan in first quarter of 2018 (IM)
  • 17 Mar 2018 Efficacy data from an exploratory analysis of a phase III trial in Pituitary ACTH Hypersecretion presented at the 100th Annual Meeting of the Endocrine Society (ENDO-2018)
  • 26 Jan 2018 Novartis withdraws phase II trial in Pituitary ACTH Hypersecretion in USA prior to enrolment, due to stringent inclusion/exclusion criteria (NCT02780882)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top